Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
Suresh Durgam,1 Changzheng Chen,1 Carl P Gommoll,1 John Edwards,1 Leslie Citrome2 1Allergan, Jersey City, NJ, USA; 2Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Background: In three 8-week studies of vilazodone 40 mg/d (NCT00285376, NCT0068...
Guardado en:
Autores principales: | Durgam S, Chen C, Gommoll CP, Edwards J, Citrome L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f233e14aa2f48458d51b48bfa95cfd5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase ME, et al.
Publicado: (2018) -
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
por: Clayton AH, et al.
Publicado: (2016) -
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
por: Weiller E, et al.
Publicado: (2017) -
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015) -
Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick D, et al.
Publicado: (2016)